The treatment with BH3-mimetics targeting BCL2 or BCL-XL also appears to be well tolerated in paediatric patients, and the combination of venetoclax with low doses of ABT263/navitoclax has been tested in paediatric acute lymphoblastic leukaemia (ALL) patients with highly promising results [34]. Here, BCL2L1 is linked to acute lymphoblastic leukemia.